Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced its second-quarter 2026 financial results, revealing a substantial reduction in operating expenses and a major regulatory milestone for its lead drug candidate. The company reported a 53% year-over-year decrease in operating expenses to $2.29 million, and a 47% reduction in general and administrative expenses to $1.76 million. This cost discipline has bolstered the company's balance sheet, with cash, cash equivalents, and digital assets totaling approximately $9.5 million as of June 30, 2026, up from $4.1 million at the end of 2025. Management states that current liquidity is sufficient to fund planned operations at least through October 2027, assuming the first-half 2026 cash burn rate.
The most significant development, however, is the FDA's approval of Quantum's Investigational New Drug (IND) application for Lucid-MS, which allows the company to proceed with a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive multiple sclerosis (MS). This approval marks a critical step forward in the development of Lucid-MS, a patented new chemical entity that has shown in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of MS.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. The company also retains a 19.84% ownership stake in Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), which markets the OTC version of UNBUZZD, and is entitled to royalty payments of 7% of sales until reaching $250 million, after which the royalty drops to 3% in perpetuity.
This financial and regulatory progress underscores Quantum's commitment to advancing its pipeline while maintaining fiscal prudence. The reduced spending and extended cash runway provide the company with the stability needed to execute its Phase 2 trial, a pivotal step toward potentially offering a new therapeutic option for patients with progressive MS. The market will be watching closely as the trial progresses, as positive results could significantly impact the company's valuation and the treatment landscape for multiple sclerosis.
For more information, visit the company's newsroom at https://nnw.fm/QNTM.
